Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SB-913
SB-913
Sangamo falls on 16-week data from gene editing trial
BioCentury
Wed, 09/5/18 - 06:39 pm
Sangamo Therapeutics
Hunter Syndrome
SB-913
Highly anticipated trial results expected soon could move all three of these biotechs
Motley Fool
Mon, 09/3/18 - 12:07 pm
Sangamo Therapeutics
Esperion Therapeutics
Loxo Oncology
SB-913
bempedoic acid
LOXO-292
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Mon, 08/13/18 - 11:26 am
TG Therapeutics
Sangamo Therapeutics
Akcea Therapeutics
FDA
Waylivra
umbralisib
SB-913
Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech
Endpoints
Wed, 11/15/17 - 11:06 am
Sangamo
gene editing
Hunter Syndrome
CRISPR
SB-913